Teriparatide biosimilar for treating osteoporosis

Published on 04 Jun 2025
Last Updated on 04 Jun 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended teriparatide biosimilar (Sondelbay) 600 mcg/2.4 mL injection for treatment of patients with severe established osteoporosis (T-score ≤ -3.0) with a history of ≥ 2 vertebral fractures or ≥ 2 fragility fractures. The maximum lifetime duration of teriparatide treatment should be limited to 24 months. The decision was based on the acceptable pricing proposal from the company.

Funding status

Teriparatide biosimilar (Sondelbay) 600 mcg/2.4 mL injection is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2025.

MAF assistance does not apply to other brand(s), formulation(s) or strengths(s) of teriparatide for treating osteoporosis.

Teriparatide biosimilar for treating osteoporosis (Published 4 Jun 2025)

PES_Anabolic drugs for treating osteoporosis (Updated 4 Jun 2025)